InsiderSignalSign in

← Insider buys

C Frank Bennett has sold IONS and made no open-market buys since Jan 2016

EVP and Chief Scientific Officer at Ionis Pharmaceuticals, Inc.

SEC CIK 0001073387 · Filings on SEC.gov ↗

$0Bought

$21.3MSold

NoneLast buy

Every filing

29 filings since Jan 2016, newest first

IONIS PHARMACEUTICALS INC

EVP and Chief Scientific Officer

$1.7M−100.0%Jul 9

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$6.7M−51.0%Mar 5

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$488K−6.0%Feb 2

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$675K−9.0%Jan 20

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$93K−2.0%Sep 4

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$92K−2.0%Feb 2

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$340K−8.0%Jan 18

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$1.1M−26.0%Dec 22

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$1.1M−26.0%Dec 18

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$207K−6.0%Sep 29

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$74K−3.0%Feb 7

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$271K−9.0%Jan 19

Ionis Pharmaceuticals Inc

Chief Scientific Officer

$406K−20.0%Dec 8

Ionis Pharmaceuticals Inc

Chief Scientific Officer

$362K−18.0%Dec 4

Ionis Pharmaceuticals Inc

Chief Scientific Officer

$702K−32.0%Nov 5

Ionis Pharmaceuticals Inc

EVP and Chief Scientific Officer

$897K−32.0%Jun 29

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$525K−27.0%Feb 5

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$619K−39.0%Nov 1

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$563K−39.0%Aug 9

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$563K−40.0%May 11

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$656K−40.0%Feb 1

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$140K−12.0%Jan 17

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$796K−45.0%Oct 20

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$593K−40.0%Jul 26

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$275K−25.0%Mar 6

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$112K−14.0%Jan 18

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$857K−68.0%Nov 14

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$170K−32.0%Nov 9

Ionis Pharmaceuticals Inc

SVP, Antisense Research

$87K−17.0%Jan 19

About C Frank Bennett

C. Frank Bennett, Ph.D. is an American pharmacologist and Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals Inc. (IONS), where he serves as a founding member responsible for advancing antisense technology, expanding the drug discovery platform, and leading the neurology franchise.( He has driven the development of antisense oligonucleotides for treating inflammatory, neurodegenerative diseases, cancer, and more, with over 230 published papers and 175 issued patents in the field.(

Bennett's career highlights include sharing the 2019 Breakthrough Prize in Life Sciences for developing an antisense therapy for spinal muscular atrophy and receiving the 2018 Hereditary Disease Foundation's Leslie Gehry Brenner Prize for innovations in Huntington's disease therapies.( Prior to Ionis, he was an associate senior investigator at SmithKline and French Laboratories (now GlaxoSmithKline).( He holds a Ph.D. in Pharmacology from Baylor College of Medicine and a B.S. in Pharmacy from the University of New Mexico.( Recently, on March 3, 2026, Bennett sold 85,089 shares of IONS stock for approximately $6.74 million while exercising options.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.